What is ROMTech?
ROMTech operates at the intersection of medical technology and orthopedic recovery, providing a groundbreaking platform designed to optimize patient outcomes. By leveraging patented rehabilitation technology, the company addresses critical inefficiencies in postoperative care, effectively reducing the overall cost of treatment while enhancing the quality of recovery for patients. The firm's market position is defined by its commitment to overhauling standard orthopedic protocols, moving away from legacy methods toward data-driven, tech-enabled recovery pathways. As a leader in the digital health space, ROMTech is actively transforming how healthcare providers deliver care, ensuring that rehabilitation is both more accessible and more effective for a wide range of orthopedic indications.
How much funding has ROMTech raised?
ROMTech has raised a total of $548.1M across 19 funding rounds:
Multiple Rounds
$548.1M
Debt (2025): $35K, investors not publicly disclosed
Debt (2025): $25K, investors not publicly disclosed
Stock/Share Issuance (2025): $1.4M, investors not publicly disclosed
Stock/Share Issuance (2025): $570K, investors not publicly disclosed
Stock/Share Issuance (2025): $665K, investors not publicly disclosed
Stock/Share Issuance (2025): $32.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $27.2M, investors not publicly disclosed
Stock/Share Issuance (2025): $20.9M, investors not publicly disclosed
Stock/Share Issuance (2025): $900K, investors not publicly disclosed
Stock/Share Issuance (2025): $35K, investors not publicly disclosed
Stock/Share Issuance (2025): $500K, investors not publicly disclosed
Stock/Share Issuance (2025): $41.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $37.2M, investors not publicly disclosed
Stock/Share Issuance (2025): $75.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $80.7M, investors not publicly disclosed
Stock/Share Issuance (2025): $49.2M, investors not publicly disclosed
Stock/Share Issuance (2025): $77.6M, investors not publicly disclosed
Stock/Share Issuance (2025): $45.4M, investors not publicly disclosed
Stock/Share Issuance (2025): $56.7M, investors not publicly disclosed
Key Investors in ROMTech
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ROMTech?
With the recent infusion of capital, ROMTech is poised to enter a new phase of enterprise-level growth. The strategic roadmap likely involves the aggressive scaling of its technological infrastructure and the expansion of its clinical footprint. By prioritizing the integration of its rehabilitation systems into major hospital networks and outpatient facilities, the company aims to solidify its market dominance. Future initiatives will likely focus on enhancing the analytical capabilities of its platform, further reducing the cost of care, and establishing new benchmarks for postoperative recovery. As the company matures, the focus will shift toward long-term sustainability and the continued refinement of its proprietary rehabilitation technology to meet the evolving demands of the global healthcare market.
See full ROMTech company page
